CRL Charles River Laboratories Inte
$358.84▲ +0.44%
Healthcare
Other
Volume 1.16M
Avg Volume (10D) 1.25M
Key Metrics & Fundamentals
Market Cap
$17.28B
P/E Ratio
–
Div Yield
0.00%
52W Range
146.20 - 359.89
% vs 50 MA
20.85%
% vs 200 MA
63.48%
RSI-14
76.8
MACD Histogram
+5.4200
Beta (1Y vs SPY)
1.28
Free Cash Flow
$148.62M
Gross Rev
$1.00B
Gross Profit
$363.37M
EBITDA
$150.80M
COGS
$640.70M
Operating Exp
$243.49M
Operating Income
$119.89M
EBIT
$119.89M
Pretax Income
$53.17M
Net Income
-$1.48M
EPS (Diluted)
-0.03
Price & Volume History
Loading chart…
Recent News
Charles River Laboratories International (CRL) Contributed to Madison Small Cap Fund’s Healthcare Outperformance
Insider Monkey · Oct 27, 2026 9:57 AM ET
Charles River Leverages Virtual Control Groups in GLP Studies
Business Wire · Oct 27, 2026 8:00 AM ET
Charles River Laboratories International Insider Sold Shares Worth $8,414,700, According to a Recent SEC Filing
MT Newswires · Oct 26, 2026 4:57 PM ET
Charles River Laboratories’ Q3 2026 Earnings: What to Expect
Barchart · Oct 26, 2026 2:32 AM ET
2 healthcare stocks to keep an eye on and 1 that underwhelm
StockStory · Oct 23, 2026 3:44 PM ET
Global Clinical Trials Market Size, Share, Growth Trends, and Forecast, 2026-2035 | Clinical Trials Market set to more than Double to $144.4bn as Drugmakers Lean on Outside Researchers
GlobeNewswire · Oct 23, 2026 9:16 AM ET
Labcorp, Charles River and FDA Partner on Drug Abuse Research
MT Newswires · Oct 22, 2026 5:55 PM ET
Charles River, Labcorp, and FDA Collaborate to Validate New Preclinical Methods for Abuse Potential Assessment
Business Wire · Oct 22, 2026 4:30 PM ET
Labcorp, Charles River and FDA Announce Research Collaboration to Advance Preclinical Methods for Evaluating Drug Abuse Potential
PR Newswire · Oct 22, 2026 4:30 PM ET
3 mid-cap stocks walking a fine line
StockStory · Oct 22, 2026 1:49 PM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See CRL's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.